



Medicare Proposes New Reimbursement Rates, L-Dex Increases

Brisbane, Australia and Carlsbad, Calif., July 12, 2016 – ImpediMed Limited (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the proposed outpatient payment rates for CY2017. This includes code 93702 for the company's L-Dex[®] procedure for the assessment of lymphedema.

Under the proposal, CMS has increased the payment rate for code 93702 when billed by a hospital outpatient facility to \$US127.42, an increase of 13.1 percent. Final payment rates will be released in November 2016, and the new rates will become effective on January 1, 2017.

Media Contacts:

Paul Maccabee/Andy Pollen, Maccabee PR,
T: +1 612-337-0087
E: paul@maccabee.com; andy@maccabee.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

###